ENLIVEN THERAPEUTICS, INC. Basic Shares Outstanding (Weighted Average)
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Basic Shares Outstanding (Weighted Average) of 66.17 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 66.17M shares, a 27.00% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 62.80M shares, a 25.47% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 62.27M shares, a 24.85% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 62.09M shares, a 28.65% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 56.66M shares, a 20.38% increase from fiscal 2024.
- ENLIVEN THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 47.07M shares, a 32.43% increase from fiscal 2023.
- ENLIVEN THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 35.55M shares, a 1037.74% increase from fiscal 2022.
- ENLIVEN THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 3.12M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic 12 month | Weighted Average Number of Shares Outstanding, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 66.17M shares 10-Q · filed 2026-08-05 | 64.49M shares 10-Q · filed 2026-08-05 | 63.75M shares derived: average of 3 quarters · filed 2026-08-05 | 63.33M shares derived: average of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | 62.80M shares 10-Q · filed 2026-05-07 | 62.54M shares derived: average of 2 quarters · filed 2026-05-07 | 62.39M shares derived: average of 3 quarters · filed 2026-05-07 | 59.82M shares derived: average of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | 62.27M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 62.18M shares derived: average of 2 quarters · filed 2026-03-03 | 58.82M shares derived: average of 3 quarters · filed 2026-08-05 | 56.66M shares 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | 62.09M shares 10-Q · filed 2025-11-12 | 57.10M shares derived: average of 2 quarters · filed 2026-08-05 | 54.79M shares 10-Q · filed 2025-11-12 | 53.53M shares derived: average of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | 52.11M shares 10-Q · filed 2026-08-05 | 51.08M shares 10-Q · filed 2026-08-05 | 50.68M shares derived: average of 3 quarters · filed 2026-08-05 | 50.08M shares derived: average of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | 50.05M shares 10-Q · filed 2026-05-07 | 49.96M shares derived: average of 2 quarters · filed 2026-05-07 | 49.40M shares derived: average of 3 quarters · filed 2026-05-07 | 49.07M shares derived: average of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | 49.88M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 49.07M shares derived: average of 2 quarters · filed 2026-03-03 | 48.74M shares derived: average of 3 quarters · filed 2026-03-03 | 47.07M shares 10-K · filed 2026-03-03 | ||||
| 2024-09-30 | 48.27M shares 10-Q · filed 2025-11-12 | 48.17M shares derived: average of 2 quarters · filed 2025-11-12 | 46.14M shares 10-Q · filed 2025-11-12 | 44.89M shares derived: average of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | 48.08M shares 10-Q · filed 2025-08-13 | 45.06M shares 10-Q · filed 2025-08-13 | 43.77M shares derived: average of 3 quarters · filed 2025-08-13 | 43.09M shares derived: average of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | 42.05M shares 10-Q · filed 2025-05-14 | 41.62M shares derived: average of 2 quarters · filed 2025-05-14 | 41.42M shares derived: average of 3 quarters · filed 2025-05-14 | 41.31M shares derived: average of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | 41.19M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 41.11M shares derived: average of 2 quarters · filed 2025-03-13 | 41.06M shares derived: average of 3 quarters · filed 2025-03-13 | 35.55M shares 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | 41.03M shares 10-Q · filed 2024-11-13 | 41.00M shares derived: average of 2 quarters · filed 2024-11-13 | 33.67M shares 10-Q · filed 2024-11-13 | 31.56M shares derived: average of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | 40.96M shares 10-Q · filed 2024-08-13 | 29.86M shares 10-Q · filed 2024-08-13 | 28.40M shares derived: average of 3 quarters · filed 2024-08-13 | 22.11M shares derived: average of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | 40.96M shares 10-Q · filed 2024-08-13 | 18.51M shares 10-Q · filed 2023-05-11 | 22.12M shares derived: average of 2 quarters · filed 2024-08-13 | 15.82M shares derived: average of 3 quarters · filed 2024-08-13 | 12.64M shares derived: average of 4 quarters · filed 2024-08-13 | |||
| 2022-12-31 | 3.28M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 3.26M shares derived: average of 2 quarters · filed 2024-03-14 | 3.21M shares derived: average of 3 quarters · filed 2024-03-14 | 3.12M shares 10-K · filed 2024-03-14 | 26.29M shares 10-K · filed 2023-02-10 | |||
| 2022-09-30 | 3.23M shares 10-Q · filed 2023-11-09 | 26.29M shares 10-Q · filed 2022-10-25 | 3.17M shares derived: average of 2 quarters · filed 2023-11-09 | 3.07M shares 10-Q · filed 2023-11-09 | 26.29M shares 10-Q · filed 2022-10-25 | -10.47M shares derived: average of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | 3.10M shares 10-Q · filed 2023-08-10 | 26.29M shares 10-Q · filed 2022-08-03 | 2.99M shares 10-Q · filed 2023-08-10 | 26.29M shares 10-Q · filed 2022-08-03 | -15.03M shares derived: average of 3 quarters · filed 2023-08-10 | -5.05M shares derived: average of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | 2.88M shares 10-Q · filed 2023-05-11 | -24.10M shares derived: average of 2 quarters · filed 2023-06-23 | -7.77M shares derived: average of 3 quarters · filed 2023-06-23 | -1.40M shares derived: average of 4 quarters · filed 2023-06-23 | ||||
| 2021-12-31 | -51.08M shares derived: 8-K 12 month − 10-Q 9 month · filed 2023-06-23 | -13.09M shares derived: average of 2 quarters · filed 2023-06-23 | -2.82M shares derived: average of 3 quarters · filed 2023-06-23 | 2.31M shares 8-K · filed 2023-06-23 | 21.66M shares 10-K · filed 2023-02-10 | |||
| 2021-09-30 | 24.90M shares 10-Q · filed 2022-10-25 | 21.31M shares derived: average of 2 quarters · filed 2022-10-25 | 20.10M shares 10-Q · filed 2022-10-25 | |||||
| 2021-06-30 | 17.72M shares 10-Q · filed 2022-08-03 | 17.65M shares 10-Q · filed 2022-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |